Back

IL-32 in limb-girdle muscular dystrophy LGMDR1-calpain 3 related: A Pilot Study on Its Role as a Biomarker

Immanuel, J.; Valls, A.; Ruiz, C.; Poza, J. J.; Garay Albizuri, P.; Fernandez Torron, R.; Lopez de Munain, A.; Saenz, A.

2025-12-19 neurology
10.64898/2025.12.18.25342268 medRxiv
Show abstract

In LGMDR1-Calpain-3 related, as in all muscular dystrophies, clinical trial monitoring remains a challenge due to the lack of reliable biomarkers. This study assessed IL-32 concentrations in both serum and urine, uncovering a marked increase in patients compared to healthy controls. Serum IL-32 levels were especially elevated in young adults, suggesting a possible link to the early and more active phases of disease onset. Meanwhile, urinary IL-32 levels showed consistent elevation across all age groups, reinforcing its promise as a stable, non-invasive biomarker. These findings support the potential of IL-32 in monitoring disease progression and therapeutic response in clinical trials, and underscore its potential involvement in LGMDR1.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.